![]() |
Open for inclusion |
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)Cancer type: Lung cancer Phase: II Principal Investigator: Helland Åslaug Country: NO Keywords: Norway, Oslo, lung, uv1, mesoteliom, nivolumab, ibilimumab Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT04300244 |